Congress Queries Drug Makers Over Measures Against Counterfeits

Law360, New York (January 19, 2004, 12:00 AM EST) -- U.S. congressional lawmakers have sent letters to five of the nation's largest drug makers, asking them to explain what they are doing to stop counterfeit drugs from entering the market.

The House Energy and Commerce Committee sent letters to Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer Inc. and Serono requesting the information by Feb. 16.

"We are interested in any ongoing efforts or plans by your company to prevent counterfeiting and diversion of your drugs, and to prevent any involvement of your products...
To view the full article, register now.